Nordic Cystectomy Study III - Transfusion

NCT04537221 | Unknown

• 1 other identifier: T199/2020
• Study Type: observational
• Target: 1,700
• Locations: 1 country
• Sites: 1

Brief Summary

Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates. The golden standard of treatment is radical cystectomy (RC) (the surgical removal of the bladder) and radical removal of lymph nodes in the pelvis. In addition to surgical treatment, and especially in cases where the tumour invades tissues surrounding the bladder or lymph nodes, chemotherapy is recommended. Chemotherapy can be administered before or after surgery, in a neoadjuvant (NAC) or adjuvant setting (AC). Although most patients recover well from surgery, there are significant risks regarding radical cystectomy. The greatest challenges in planning the treatment are making individual risk assessments and prognosis for the treated patients. Neoadjuvant chemotherapy is also insufficiently used and it is hard to predict how the tumour responds to chemotherapy. The purpose of this study is to collect prospective clinical data on radical cystectomy -patients in co-operation with other Nordic countries: Sweden, Denmark, Iceland and Norway. The collected data is used to validate existing prediction tools and discover novel tools for prediction of morbidity related to RC and prediction of oncological outcome after RC. The study is divided into three sub-studies. Transfusions during RC and the time of hospitalization after the surgery are associated poorer oncological outcome when compared to those patients who do not need transfusions. The third study focuses on the oncological outcomes in patients receiving blood transfusions. As there are some conflicting reports and the finding is not properly validated, we aim to validate the effect of transfusions on survival after RC. The number of transfusions during RC and the time between surgery and discharge from hospital will be recorded. Patient cohort will be divided into patients receiving transfusions and not receiving transfusion. The primary end point is patients receiving transfusion and its effect on cancer specific mortality at 24 months. For patients receiving NAC, additional secondary end-point is complete response (pT0N0) rate at RC.

Conditions

Bladder Cancer; Invasive Bladder Cancer

Outcome Measures

Primary Outcomes (1)

• Perioperative blood transfusion (PBT) effect on cancer specific mortality

  Comparison of cancer-specific-mortality between patients receiving one or more PBT perioperatively vs. patients receiving none

  24 months

Study Arms (2)

No transfusions

Patients receiving no perioperative blood transfusions (PBT)

Biological: Blood transfusion

Transfusions

Patients receiving perioperative blood transfusions (PBT)

Biological: Blood transfusion

Interventions

Blood transfusion BIOLOGICAL

Transfusion of red blood cells peri-operatively

No transfusions; Transfusions

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with muscle-invasive bladder cancer undergoing radical cystectomy -surgery

You may qualify if:

• Histologically confirmed urinary BC planned to be treated with RC with or without neoadjuvant chemotherapy.
• Histologically confirmed urinary BC planned to be treated with palliative cystectomy
• Signed informed consent
• Patient age \>18 years

You may not qualify if:

• RC for other reasons than BC
• Other forms of surgical treatment of BC than RC (e.g. bladder resection).
• Patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).

Sponsors & Collaborators

• Turku University Hospital: lead
• Nordic Urothelial Cancer Group: collaborator

Study Sites (1)

University Hospital of Turku, Hospital Distric of Southwest Finland

Turku, Southwest Finland, 20521, Finland

RECRUITING

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Blood Transfusion

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Biological Therapy; Therapeutics

Study Officials

• Peter Boström, MD, PhD

  Turku University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Otto Ettala, MD, PhD

CONTACT

23130280; otto.ettala@tyks.fi

Ilkka Nikulainen, MD

CONTACT

23137928; ilkka.nikulainen@tyks.fi

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 24 Months
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2020
• First Posted: September 3, 2020
• Study Start: September 30, 2020
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: November 25, 2020

Record last verified: 2020-11

Data Sharing

• IPD Sharing: Will not share

Locations

FI (1)